作者
Peter N Taylor, Kimberly S Collins, Anna Lam, Stephen R Karpen, Brianna Greeno, Frank Walker, Alejandro Lozano, Elnaz Atabakhsh, Simi T Ahmed, Marjana Marinac, Esther Latres, Peter A Senior, Mark Rigby, Peter A Gottlieb, Colin M Dayan, Carla Greenbaum, Jeffrey Krisher, Jay Skyler, Diane Wherrett, Ulf Hannelius, Anton Lindqvist, Christoph Nowak, Ionut Bebu, Barbara Braffett, Antonella Napolitano, Salim Jan Mohamed, Gordon Weir, Gerald Nepom, Roy Beck, Claudia Richard, Joseph Hedrick, Johnny Ludvigsson, Matthias Von Herrath, Francisco Leon, Eleanor Ramos, Parth Narendran, Stephen Gitelman, Dana Dabelea, Rob Andrews, Michael Haller, Elizabeth Jensen, Kevan Harold, Jan Dutz
发表日期
2023/12/1
期刊
Lancet Diabetes Endocrinol
卷号
11
期号
12
页码范围
915-925
出版商
Elsevier
简介
Background
Metabolic outcomes in type 1 diabetes remain suboptimal. Disease modifying therapy to prevent β-cell loss presents an alternative treatment framework but the effect on metabolic outcomes is unclear. We, therefore, aimed to define the relationship between insulin C-peptide as a marker of β-cell function and metabolic outcomes in new-onset type 1 diabetes.
Methods
21 trials of disease-modifying interventions within 100 days of type 1 diabetes diagnosis comprising 1315 adults (ie, those 18 years and older) and 1396 children (ie, those younger than 18 years) were combined. Endpoints assessed were stimulated area under the curve C-peptide, HbA1c, insulin use, hypoglycaemic events, and composite scores (such as insulin dose adjusted A1c, total daily insulin, U/kg per day, and BETA-2 score). Positive studies were defined as those meeting their primary endpoint. Differences in outcomes between …
学术搜索中的文章
PN Taylor, KS Collins, A Lam, SR Karpen, B Greeno… - The Lancet Diabetes & Endocrinology, 2023
